NASDAQ:IMCR - Immunocore Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $54.33
  • Forecasted Upside: 38.64 %
  • Number of Analysts: 3
  • Breakdown:
  • 0 Sell Ratings
  • 1 Hold Ratings
  • 2 Buy Ratings
  • 0 Strong Buy Ratings
$39.19
▲ +0.94 (2.46%)
1 month | 3 months | 12 months
Get New Immunocore Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for IMCR and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for IMCR

i We calculate consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). Our consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. Our consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
$54.33
▲ +38.64% Upside Potential
This price target is based on 3 analysts offering 12 month price targets for Immunocore in the last 3 months. The average price target is $54.33, with a high forecast of $65.00 and a low forecast of $40.00. The average price target represents a 38.64% upside from the last price of $39.19.
Buy
The current consensus among 3 contributing investment analysts is to buy stock in Immunocore.

Past Monthly Recommendations

Move your mouse over past months for details

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
10/27/2019
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
1/25/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/24/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
7/23/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
10/21/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
1/19/2021
  • 0 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 0 sell ratings
3/20/2021
  • 0 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 0 sell ratings
4/19/2021

Latest Recommendations

  • 0 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 0 sell ratings

DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
3/8/2021The Goldman Sachs GroupInitiated CoverageNeutral$40.00N/A
i
3/8/2021Jefferies Financial GroupInitiated CoverageBuy$65.00N/A
i
3/2/2021JPMorgan Chase & Co.Initiated CoverageOverweight$58.00Medium
i
3/2/2021Jefferies Financial GroupInitiated CoverageBuy$65.00Medium
i
3/2/2021The Goldman Sachs GroupInitiated CoverageNeutral$40.00Medium
i
(Data available from 4/19/2016 forward)
Immunocore logo
Immunocore Holdings Limited, a late-stage biotechnology company, develops immunotherapies for the treatment of oncology, infectious, and autoimmune diseases. The company's lead oncology therapeutic candidate is tebentafusp, which is in a randomized Phase III clinical trial in patients with previously untreated metastatic uveal melanoma, a cancer that has historically proven to be insensitive to other immunotherapies. Its other programs for oncology comprise IMC-C103C that is in Phase I/II dose escalation trial in patients with solid tumor cancers, including non-small-cell lung, gastric, head and neck, ovarian, and synovial sarcoma cancers; IMC-F106C, which is in a Phase I/II dose escalation trial in patients with multiple solid tumor cancers comprising breast, endometrial, ovarian, and small cell lung cancers; and GSK01 that is in a Phase I clinical trial. In addition, the company's programs for infectious diseases include IMC-I109V, which is in a Phase I/II clinical trial in patients with chronic hepatitis B virus; and IMC-M113V that is in pre-clinical development stage. Further, it develops product candidates to provide precision targeted immunosuppression for the treatment of autoimmune diseases. The company was founded in 1999 and is headquartered in Abingdon, the United Kingdom.
Read More

Today's Range

Now: $39.19
$36.92
$40.09

50 Day Range

MA: $40.78
$32.22
$51.13

52 Week Range

Now: $39.19
$30.92
$61.99

Volume

75,508 shs

Average Volume

120,053 shs

Market Capitalization

$1.69 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Frequently Asked Questions

What sell-side analysts currently cover shares of Immunocore?

The following Wall Street sell-side analysts have issued stock ratings on Immunocore in the last twelve months: Jefferies Financial Group Inc., JPMorgan Chase & Co., and The Goldman Sachs Group, Inc..
View the latest analyst ratings for IMCR.

What is the current price target for Immunocore?

3 Wall Street analysts have set twelve-month price targets for Immunocore in the last year. Their average twelve-month price target is $54.33, suggesting a possible upside of 38.6%. Jefferies Financial Group Inc. has the highest price target set, predicting IMCR will reach $65.00 in the next twelve months. The Goldman Sachs Group, Inc. has the lowest price target set, forecasting a price of $40.00 for Immunocore in the next year.
View the latest price targets for IMCR.

What is the current consensus analyst rating for Immunocore?

Immunocore currently has 1 hold rating and 2 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe IMCR will outperform the market and that investors should add to their positions of Immunocore.
View the latest ratings for IMCR.

What other companies compete with Immunocore?

How do I contact Immunocore's investor relations team?

The company's listed phone number is 44 1235 438600. The official website for Immunocore is www.immunocore.com.